Trial Profile
A Phase IIa, 3 Strata Dose-Defining Study Evaluating the Hemodynamic Effects, Safety and Tolerability of CXL-1020 in Patients With Systolic Heart Failure.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs CXL 1020 (Primary)
- Indications Heart failure
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Cardioxyl Pharmaceuticals
- 13 Apr 2012 Actual patient number (69) added as reported by ClinicalTrials.gov.
- 13 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2011 Planned end date changed from 1 Feb 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.